Pooled Data Show Optinose's XHANCE Cut Sinusitis Flares By 66%

Comments
Loading...
  • Optinose Inc OPTN announced the results of pre-planned analyses from the ReOpen trial program evaluating XHANCE for chronic sinusitis. 
  • XHANCE (fluticasone propionate) nasal spray is a drug-device combination product that delivers high and deep in nasal passages with an anti-inflammatory drug. 
  • These analyses of pooled data from the ReOpen1 and ReOpen2 trials found that over 24 weeks of follow-up, patients using XHANCE two sprays per nostril (372 mcg) twice daily had a 66% reduction in the number of disease exacerbations compared to patients receiving a placebo comparator.
  • Related: Optinose Shared Additional Encouraging Data From Late-Stage Chronic Sinusitis Studies.
  • In additional exploratory pre-planned analyses, similar reductions (ranging from 53 to 80%) in the number of exacerbations were also found for patients taking XHANCE one spray per nostril (186 mcg) twice daily and in subgroups with or without nasal polyps.
  • The program was generally consistent with its currently labeled safety profile.
  • Price Action: OPTN shares are up 2.07% at $3.71 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!